C. Koop

发表

Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer.

Amos Tanay, Mathieu Lupien, Joachim Weischenfeldt, 2014, Cell reports.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Takafumi N. Yamaguchi, C. von Kalle, R. Eils, 2018, Cancer cell.

Molecular Evolution of Ear ly-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories Graphical

Takafumi N. Yamaguchi, R. Eils, J. Korbel, 2018 .

Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer

G. Sauter, T. Schlomm, S. Steurer, 2015, Oncotarget.

MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large‐scale tissue microarrays

Malte Buchholz, Michael Becker, Dennis Trede, 2013, International journal of cancer.

Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders.

H. Kreipe, G. Büsche, O. Bock, 2006, The Journal of molecular diagnostics : JMD.

PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort

G. Sauter, T. Schlomm, J. Hicks, 2017, Oncotarget.

Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.

A. Haese*, G. Sauter, T. Schlomm, 2015, Oncology reports.

Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.

G. Sauter, T. Schlomm, S. Steurer, 2016, Human pathology.

The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG‐negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression

G. Sauter, T. Schlomm, S. Steurer, 2014, International journal of cancer.

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers

G. Sauter, T. Schlomm, S. Steurer, 2015, PloS one.

Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays

G. Sauter, A. Marx, R. Simon, 2015, Pathology & Oncology Research.

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.

G. Sauter, T. Schlomm, S. Steurer, 2015, Carcinogenesis.

Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer

J. Korbel, A. Haese*, G. Sauter, 2014, International journal of cancer.

Diverse expression patterns of the EMT suppressor grainyhead‐like 2 (GRHL2) in normal and tumour tissues

G. Sauter, V. Assmann, R. Simon, 2016, International journal of cancer.

PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort

G. Sauter, T. Schlomm, J. Hicks, 2017, Oncotarget.

Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG‐fusion positive and PTEN deleted prostate cancers

G. Sauter, T. Schlomm, A. Marx, 2016, International journal of cancer.

The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion

G. Sauter, T. Schlomm, S. Steurer, 2015, BMC Cancer.

Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer

G. Sauter, T. Schlomm, S. Steurer, 2015, Oncotarget.

NY‐ESO‐1 expression is tightly linked to TMPRSS2–ERG fusion in prostate cancer

G. Sauter, T. Schlomm, S. Steurer, 2014, The Prostate.

High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers

G. Sauter, T. Schlomm, R. Simon, 2013, Molecular oncology.

High mitochondria content is associated with prostate cancer disease progression

G. Sauter, T. Schlomm, S. Steurer, 2013, Molecular Cancer.

VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy

G. Sauter, T. Schlomm, S. Steurer, 2015, International journal of molecular sciences.

p16 upregulation is linked to poor prognosis in ERG negative prostate cancer

G. Sauter, T. Schlomm, T. Krech, 2016, Tumor Biology.

Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer

G. Sauter, T. Schlomm, S. Steurer, 2016, The Prostate.

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

A. Haese*, G. Sauter, T. Schlomm, 2016, Clinical Cancer Research.

High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer

A. Haese*, G. Sauter, T. Schlomm, 2015, PloS one.

HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.

G. Sauter, T. Schlomm, S. Steurer, 2015, Experimental and molecular pathology.

Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer

G. Sauter, T. Schlomm, S. Steurer, 2015, Clinical Cancer Research.

Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.

G. Sauter, T. Schlomm, S. Steurer, 2015, Human pathology.

HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy

G. Sauter, T. Schlomm, S. Steurer, 2015, Oncotarget.

TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.

J. Korbel, C. Plass, G. Sauter, 2014, European Urology.

Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer

G. Sauter, T. Schlomm, S. Steurer, 2014, Microarrays.

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer

G. Sauter, R. Simon, M. Kluth, 2016, Oncotarget.

High concordance of findings obtained from transgluteal magnetic resonance imaging ‐ and transrectal ultrasonography‐guided biopsy as compared with prostatectomy specimens

G. Sauter, T. Schlomm, S. Steurer, 2017, BJU international.

βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma

G. Sauter, T. Schlomm, S. Steurer, 2015, World Journal of Urology.

MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays.

H. Schlüter, G. Sauter, S. Steurer, 2017, Journal of mass spectrometry : JMS.

βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.

G. Sauter, S. Steurer, T. Clauditz, 2017, Human pathology.

Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.

A. Haese*, G. Sauter, T. Schlomm, 2018, European urology.

Abstract 572: Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG fusion positive, PTEN deleted prostate cancers

G. Sauter, T. Schlomm, S. Steurer, 2014 .

Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome

G. Sauter, S. Steurer, T. Krech, 2018, BMC Cancer.

Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome

G. Sauter, S. Steurer, T. Krech, 2018, BMC Cancer.

Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer

G. Sauter, T. Schlomm, S. Steurer, 2015, OncoTarget.

Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer

G. Sauter, T. Schlomm, S. Steurer, 2015, Clinical Cancer Research.

Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation and Genomic Instability in Prostate Cancer Statement of Translational Relevance

T. Schlomm, S. Steurer, C. Wittmer, 2022 .

Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG‐fusion positive and PTEN deleted prostate cancers

G. Sauter, T. Schlomm, A. Marx, 2016, International journal of cancer.